Skip to main content

Dystonia Medical Research Foundation Honors Two Warren Men for Promoting Awareness of Debilitating Disease

Jason Dunn and Mike Delise recently returned from the Children & Family Dystonia Symposium in Chicago, where they were presented with Star Awards. The Dystonia Medical Research Foundation (DMRF) recognized Dunn and Delise for their efforts to promote greater public awareness of dystonia, a neurological disease.

"I think this is probably the only time in my life that I am speechless," says Dunn. "I wasn't expecting this award at all."

"Bringing awareness and donations to the Dystonia Medical Research Foundation is the single most important thing we can do--this is how a cure will be found," says Delise. "The people who deserve this award are all the people who have dystonia who bring awareness every minute of their life. Jason is my hero and to be able to help your hero is a thrill for me."

Dunn began exhibiting unusual postures and an awkward gait at age 6. While most children this age are mastering their abilities to run, jump, and somersault, Dunn was struggling. Over the next few years, his body was consumed by unrelenting, involuntary muscle spasms that made it difficult or impossible to walk, sit, write, and speak.

When Dunn was in high school, he met and made a powerful impression on Delise, the father of one of Dunn's peers. Delise became an uncle figure and buddy to Dunn, frequently inviting Dunn to his home and sharing his enthusiasm for Detroit sports teams, especially Lions football. Delise has also supported Dunn's desires to promote greater awareness of dystonia by working with local news media and using online social networks. The pair has organized fundraisers on behalf of the DMRF. Because dystonia prevents Dunn from communicating verbally, the two joke that Delise has taken on the role of Dunn's "agent" by making phone calls and coordinating arrangements.

In 2010, Dunn and Delise were featured on the television program, Extraordinary Humans: Muscles, produced by the National Geographic Channel. The program provided a detailed look into how dystonia affects Dunn' daily life. Extraordinary Humans: Muscles was premiered in June 2010 and was re-aired in the following weeks, including internationally and in Spanish, reaching millions of viewers and earning Dunn a large online following.

"Jason and Mike make an impressive team," says DMRF Executive Director Janet Hieshetter. "It takes courage to share your life on national television. They have done an amazing job promoting awareness of dystonia in the Detroit area and around the world."

Dystonia is a movement disorder that causes muscles to contract and spasm involuntarily resulting in twisting, repetitive movements and abnormal postures. Dystonia affects men, women, and children. There is no known cure.

Founded in 1976, the Dystonia Medical Research Foundation is a 501c3 organization whose mission is to advance research toward improved treatments and a cure, promoting education and awareness, and providing support resources to affected individuals and families. The organization can be reached at http://www.dystonia-foundation.org or 800-377-DYST (3978).

Contact: Jessica Feeley, Ph: 912-510-0337, jfeeley@dystonia-foundation.org

Source: Dystonia Medical Research Foundation.
Labels:

Comments

Post a Comment

Popular posts from this blog

Drug Delivery to the Brain for Alzheimer's

Source: Cornell University . Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered. The researchers found that adenosine, a molecule produced by the body, can modulate the entry of large molecules into the brain. For the first time, the researchers discovered that when adenosine receptors are activated on cells that comprise the blood-brain barrier, a gateway into the blood-brain barrier can be established. Although the study was done on mice, the researchers have also found adenosine receptors on these same cells in humans. They also discovered that an existing FDA-approved drug called Lexiscan, an adenosine-based drug used in heart imaging in very ill patients, can also briefly open the gateway across the blood-brain barrier. The blood-brain bar...
Post a Comment
Read more

Human Brain Doesn't Stop Developing at Adolescence

Source: University of Alberta Faculty of Medicine & Dentistry. The human brain doesn't stop developing at adolescence, but continues well into our 20s, demonstrates recent research from the Faculty of Medicine & Dentistry at the University of Alberta.  It has been a long-held belief in medical communities that the human brain stopped developing in adolescence. But now there is evidence that this is in fact not the case, thanks to medical research conducted in the Department of Biomedical Engineering by researcher Christian Beaulieu, an Alberta Innovates -- Health Solutions scientist, and by his PhD student at the time, Catherine Lebel. Lebel recently moved to the United States to work at UCLA, where she is a post-doctoral fellow working with an expert in brain-imaging research. "This is the first long-range study, using a type of imaging that looks at brain wiring, to show that in the white matter there are still structural changes happening during young adult...
Post a Comment
Read more

J147 Reverses Memory Deficits And Slows Alzheimer's In Mice

Source:  Salk Institute A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment. The findings, published May 14 in the journal Alzheimer's Research and Therapy, may pave the way to a new treatment for Alzheimer's disease in humans.  "J147 is an exciting new compound because it really has strong potential to be an Alzheimer's disease therapeutic by slowing disease progression and reversing memory deficits following short-term treatment," says lead study author Marguerite Prior, a research associate in Salk's Cellular Neurobiology Laboratory. Despite years of research, there are no disease-modifying drugs for Alzheimer's. Current FDA-approved medications, including Aricept, Razadyne and Exelon, offer only fleeting short-term benefits for Alzheimer's patients, but they do nothing to slow the steady, irr...
Post a Comment
Read more